Don't know about the separate entity, it's one way of isolating Intellicell but it doesn't remove the problem.
I personally think they should use Intellicell and work with what they have; if it works as advertised, there will be multiple revenue streams coming on line, especially if the European patent is awarded.
There have been some large, multi-million share purchases going on over the last couple of months (at the moment it can't be conversions as there's NO BID so no-one is selling other than the MMs. Point is someone is accumulating, we don't know who or why but it is feasible that it is an investor buying shares to eventually retire them which lessens the need for RS AND helps get the shares under control.
This could be an investor playing the long game here, recognizing that there's more to be had by staying with Intellicell for the journey and by removing shares from circulation. Anyone have an idea what the float is, there could be a lot locked up which could make a price movement go quickly. We just don't know...
Remember that if minimal manipulation and safety/efficacy are proved, this opens the door for everyone else doing INDs to use our extraction process which equals lots more labs plus revenue for each patient - on multiple INDs that could be a lot of revenue very quickly...
thoughts???
News 
Market Data 
Discover 
AI
